UNITED THERAPEUTICS Corp Files 8-K
Ticker: UTHR · Form: 8-K · Filed: Mar 30, 2026 · CIK: 0001082554
| Field | Detail |
|---|---|
| Company | United Therapeutics Corp (UTHR) |
| Form Type | 8-K |
| Filed Date | Mar 30, 2026 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-k, financial-statements, exhibits
Related Tickers: UTHR
TL;DR
UTHR filed an 8-K on 3/30/26 with financial exhibits.
AI Summary
On March 30, 2026, UNITED THERAPEUTICS Corp filed an 8-K report detailing other events and financial statements. The filing includes exhibits such as financial statements and interactive data. The company's mailing and business address is 1000 SPRING ST, SILVER SPRING, MD 20910.
Why It Matters
This 8-K filing provides updated information and financial exhibits for UNITED THERAPEUTICS Corp, which is crucial for investors and stakeholders to assess the company's current status.
Risk Assessment
Risk Level: low — This filing is a routine 8-K report and does not appear to contain any significant new risks or material adverse events.
Key Players & Entities
- UNITED THERAPEUTICS Corp (company) — Filer of the 8-K report
- 2026-03-30 (date) — Filing date and period of report
- 1000 SPRING ST SILVER SPRING MD 20910 (address) — Mailing and business address of the company
FAQ
What type of report did UNITED THERAPEUTICS Corp file?
UNITED THERAPEUTICS Corp filed a Form 8-K, which is a Current Report.
When was the 8-K filing accepted by the SEC?
The 8-K filing was accepted on March 30, 2026, at 07:00:25.
What are the main items covered in this 8-K filing?
This 8-K filing covers Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits).
What is the CIK number for UNITED THERAPEUTICS Corp?
The CIK number for UNITED THERAPEUTICS Corp is 0001082554.
What is the business address of UNITED THERAPEUTICS Corp?
The business address of UNITED THERAPEUTICS Corp is 1000 SPRING ST, SILVER SPRING, MD 20910.
Filing Stats: 427 words · 2 min read · ~1 pages · Grade level 11.1 · Accepted 2026-03-30 07:00:25
Key Financial Figures
- $0.01 — h registered Common Stock, par value $0.01 per share UTHR Nasdaq Global Select
Filing Documents
- tm2610558d1_8k.htm (8-K) — 27KB
- tm2610558d1_ex99-1.htm (EX-99.1) — 32KB
- tm2610558d1_ex99-1img001.jpg (GRAPHIC) — 2KB
- 0001104659-26-036445.txt ( ) — 232KB
- uthr-20260330.xsd (EX-101.SCH) — 3KB
- uthr-20260330_lab.xml (EX-101.LAB) — 33KB
- uthr-20260330_pre.xml (EX-101.PRE) — 22KB
- tm2610558d1_8k_htm.xml (XML) — 3KB
01. Other Events
Item 8.01. Other Events On March 30, 2026, United Therapeutics Corporation issued a press release announcing positive results of the TETON-1 clinical study of Tyvaso (treprostinil) Inhalation Solution in patients with idiopathic pulmonary fibrosis. The press release is attached as Exhibits 99.1 and is incorporated herein by reference. TYVASO is a registered trademark of United Therapeutics Corporation.
01. Exhibits
Item 9.01. Exhibits (d) Exhibits Exhibit No. Description of Exhibit 99.1 Press Release dated March 30, 2026 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. UNITED THERAPEUTICS CORPORATION Dated: March 30, 2026 By: /s/ Paul A. Mahon Name: Paul A. Mahon Title: General Counsel